Brian T. Hill MD, PhD
Disclosures
Hill reports research funding from and/or consulting roles with AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Genentech and Gilead Sciences/Kite Pharma.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
The management of patients with mantle cell lymphoma that's been previously treated, can be a little tricky. Usually, for patients that we're seeing in the current era, they would have most likely have been treated with a chemoimmunotherapy regimen as their frontline treatment. Commonly used treatments might have been bendamustine-rituximab (Rituxan; Genentech, Biogen), ideally followed by rituximab maintenance therapy, often with or without autologous stem cell transplant. But in the community, we know, most patients actually don't or haven't under gone autologous stem cell transplant, and there may be reasons to not do autologous stem cell transplant in the current era. But for the patients who are out there now who have been previously treated, let's say, with bendamustine-rituximab and rituximab maintenance, if they achieved remission for some period of time and now are relapsing, the optimal approach is along a, a couple of different lines, but usually is going to invoke a BTK inhibitor.
